Japan Allergy Diagnostics And Therapeutics Market Size & Outlook
Japan allergy diagnostics and therapeutics market, 2018-2030 (US$M)
Related Markets
Japan allergy diagnostics and therapeutics market highlights
- The Japan allergy diagnostics and therapeutics market generated a revenue of USD 2,341.5 million in 2023 and is expected to reach USD 3,669.1 million by 2030.
- The Japan market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, inhaled was the largest revenue generating allergen type in 2023.
- Other Allergens is the most lucrative allergen type segment registering the fastest growth during the forecast period.
Allergy diagnostics and therapeutics market data book summary
| Market revenue in 2023 | USD 2,341.5 million |
| Market revenue in 2030 | USD 3,669.1 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Inhaled |
| Fastest growing segment | Other Allergens |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inhaled, Drug, Other Allergens, Food |
| Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Other key industry trends
- In terms of revenue, Japan accounted for 7.5% of the global allergy diagnostics and therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan allergy diagnostics and therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 683.8 million by 2030.
Inhaled was the largest segment with a revenue share of 55.08% in 2023. Horizon Databook has segmented the Japan allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
The allergy diagnostics and therapeutics market is projected to showcase lucrative growth over the forecast period due to increasing prevalence of allergy cases, rising awareness about early diagnosis, and availability of a wide range of therapeutics. Furthermore, rising number of key players focusing on the development of new products, and increasing number of clinical trials in the country are fueling the market growth.
For instance, in October 2022, ARS Pharmaceuticals announced that the U.S. FDA accepted a New Drug Application (NDA) for its neffy nasal epinephrine device for the emergency treatment of anaphylaxis in children and adults. Some of the key players in the market are AbbVie, Inc., Allergy Therapeutics, and Pfizer, Inc.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Diagnostics And Therapeutics Market Scope
Allergy Diagnostics And Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan allergy diagnostics and therapeutics market size, by allergen type, 2018-2030 (US$M)
Japan Allergy Diagnostics And Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
